2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1781 Real-world outcomes with Bruton’s tyrosine kinase inhibitors in patients with waldenstrom macroglobulinemia

Gunjan Gaur, MD, Jithma Abeykoon, MD2, Jonas Paludo, MD3, Morie Gertz, MD4, Shaji Kumar, MD5, Rebecca L King, MD6, Thomas M. Habermann, MD7, Ronald Go, MD8, Joselle M Cook, M.D.9, Nadine Abdallah I, MD10, Gita Thanarajasingam, MD11, Francis Buadi, MD12, Angela Dispenzieri, MD13, Carrie Thompson, MD14, Patrizia Mondello, MD, PhD15, Wilson Gonsalves, MD16, Grzegorz Nowakowski, MD17, David Dingli, MD, PhD18, Eli Muchtar, MD19, Patricia Greipp, DO20, Surendra Dasari, Associate Professor21, Joseph Peter Novak, MS22, Rahma Warsame, MD23, Thomas Witzig, MD24, S. Vincent Rajkumar, MD25, Stephen Maxted Ansell, MD, PhD26, Prashant Kapoor, MD27, Saurabh Zanwar, MBBS, MD28
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States
26 Mayo Clinic, Rochester, Minnesota, United States
27 Mayo Clinic, Rochester, Minnesota, United States
28 Mayo Clinic, Rochester, Minnesota, United States

Background: Bruton’s tyrosine kinase inhibitors (BTKis) are effective therapies for Waldenström macroglobulinemia (WM), particularly in MYD88L265P-mutated disease, but comparative real-world data are limited. We evaluated survival and toxicity outcomes of BTKi therapy in routine clinical practice.

Methods: We retrospectively reviewed patients with WM treated with ibrutinib or zanubrutinib monotherapy between January 2015 and March 2026 in treatment-naïve (TNWM) or relapsed/refractory (RRWM) settings. Progression-free survival (PFS) was defined as time from BTKi initiation to progression or death. Patients stopping due to toxicity but not progressed were censored for PFS calculation at the date of stopping.  Event-free survival (EFS) was time from BTKi initiation to progression, death, or discontinuation due to adverse effects.

Results: 392 patients (463 BTKi treatment initiations) were identified. Median follow-up from BTKi initiation was 6.1 years for ibrutinib and 1.9 years for zanubrutinib. 327/463 initiations (70.6%) were in RRWM. Ibrutinib use was more frequent than zanubrutinib (249 initiations [53.7%] vs 214 [46.2%]). Among those tested, 87.7% (283/323) had MYD88L265P mutations; 33.9% (44/124) had CXCR4 mutations. Baseline clinical characteristics were similar between BTKis.

Best response on BTKi was determined for 215 patients. In TNWM, objective response rate (ORR) was 91.3% (21/23) with ibrutinib and 90.7% (39/43) with zanubrutinib; major response rate (MRR) was 56.5% (13/23) and 74.4% (32/43), respectively (p=0.33). In RRWM, ORR was 86.3% (69/80) and 83.8% (56/67), and MRR was 76.3% (61/80) and 63.5% (47/74) respectively (p=0.22).

With ibrutinib, 2- and 4-year PFS rates were 72.6% (95% CI: 66.8–78.9%) and 54.7% (95% CI: 47.9–62.4%), respectively, with median PFS of 4.8 years (95% CI: 3.9-6). Corresponding PFS rates with zanubrutinib were 77.3% (95% CI: 70.6–84.7%) and 65.0% (95% CI: 55.0-76.8%), with median PFS not reached (NR) (95% CI: 4.4–NR). There was no difference in PFS between ibrutinib and zanubrutinib (p=0.17), but median EFS was longer with zanubrutinib vs. ibrutinib (3.1 years [95% CI: 2.1–NR] vs 1.5 years [95% CI: 1.4–2.5]; p=0.03). In a multivariable analysis including type of BTKi, TNWM vs. RRWM, age >65 years and MYD88L265P genotype, zanubrutinib demonstrated improved EFS (hazard ratio [HR] 0.7 [95% CI: 0.52-0.94], p=0.02), whereas there was no statistically significant difference in PFS (HR 0.74 [95% CI: 0.49-1.13]; p=0.17).

In TNWM, 2-year PFS rate was numerically higher with zanubrutinib than ibrutinib (81.5% [95% CI: 71.0–93.6%] vs 68.6% [95% CI: 56.7-82.9%]; p=0.09), whereas median PFS was similar in RRWM (4.4 [95% CI: 3.3–NR] vs 4.8 years [95% CI: 3.7–5.9]; p=0.55). No significant differences in PFS were observed between BTKis within MYD88L265P, MYD88WT, CXCR4MUT or CXCR4WT subgroups.

In the ibrutinib cohort, median PFS was numerically longer in MYD88L265P vs. MYD88WT WM (4.7 [95% CI: 3.6-5.6] vs 2.0 years [95% CI:1–NR]; p=0.38) and in CXCR4WT vs. CXCR4MUT WM (5.6 [95% CI: 4.5–NR] vs 3.4 years [95% CI: 2.5–NR]; p=0.07). For zanubrutinib, median PFS was NR (95% CI: 1.8–NR) in MYD88L265P vs. 3.3 years (95% CI: 4.4–NR) in MYD88WT WM (p=0.09) and was NR irrespective of CXCR4 status (p=0.87).

39.2% (181/462) of treatments were stopped due to toxicity, more often with ibrutinib than zanubrutinib (119/249 [47.8%] vs 62/213 [29.1%]; p<0.001). Common reasons for discontinuation were cardiovascular events (29 patients [24.4%] vs 8 [11.3%]; p=0.05), bleeding/bruising (11 [9.2%] vs 9 [15.5%]; p=0.32), and infection (14 [11.8%] vs 7 [11.3%]; p=0.93) for ibrutinib and zanubrutinib, respectively. Atrial fibrillation occurred in more patients on ibrutinib than zanubrutinib (54 [21.7%] vs 10 [4.7%]; p<0.001).  Occurrences of hypertension (28 [11.2%] vs 15 [7.0%]; p=0.12), infection requiring hospitalization (27 [10.8%] vs 19 [8.9%]; p=0.48), and bleeding requiring treatment interruption (11 [6.8%] vs 9 [6.1%]; p=0.74) were similar between ibrutinib and zanubrutinib, respectively.

Conclusion: In this real-world cohort, both ibrutinib and zanubrutinib achieved high response rates and demonstrated comparable PFS. Zanubrutinib was associated with longer EFS, fewer treatment discontinuations, and less cardiovascular toxicity, particularly atrial fibrillation. These findings support individualized BTKi selection based on toxicity profile and patient comorbidities.

Gunjan Gaur, MD: No relevant conflicts of interest to declare.